Literature DB >> 25643369

Comparison of the Plusoptix A09 and Retinomax K-Plus 3 with retinoscopy in children.

Ihsan Yilmaz, Abdullah Ozkaya, Zeynep Alkin, Sifa Ozbengi, Ahmet Taylan Yazici, Ahmet Demirok.   

Abstract

PURPOSE: To compare refractive measurements between the Plusoptix A09 (Plusoptix GmbH, Nuremberg, Germany), Retinomax K-Plus 3 (Right Med, Virginia Beach, VA), and retinoscopy in pediatric patients.
METHODS: Two hundred eyes of 200 patients (94 female, 106 male) were included in this cross-sectional study. Non-cycloplegic refraction was measured via the Plusoptix A09 and cycloplegic refraction was measured via the Retinomax K-Plus 3 and retinoscopy. Each device was evaluated for repeatability. The average measurements from all devices were compared.
RESULTS: The mean age of the patients was 6.2 ± 2.8 years (range: 4 to 12 years). The mean non-cycloplegic refraction via Plusoptix A09 was 0.74 ± 1.85 diopters (D) spherical and -0.79 ± 0.78 D cylindrical. The mean cycloplegic refraction via the Retinomax K-Plus 3 was 0.13 ± 1.92 D spherical and -0.74 ± 0.69 D cylindrical. The mean cyloplegic retinoscopy measurement was 0.71 ± 1.81 D spherical and -0.70 ± 0.76 D cylindrical. There was no significant difference between measurements (P = .07).
CONCLUSIONS: The Plusoptix A09 and Retinomax K-Plus 3 agree well with cycloplegic retinoscopy. Both devices may be used for screening children between 4 and 12 years old. The Plusoptix A09 may eliminate the need for cycloplegia for the detection of refractive errors in children. Copyright 2015, SLACK Incorporated.

Entities:  

Mesh:

Year:  2015        PMID: 25643369     DOI: 10.3928/01913913-20141230-06

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  8 in total

1.  Performance of Plusoptix A09 Photo Screener in Refractive Error Screening in School Children Aged between 5 and 15 Years in the Southern Part of India.

Authors:  Avinash V Prabhu; Jyothi Thomas; Ramesh S Ve; Sayantan Biswas
Journal:  J Curr Ophthalmol       Date:  2020-07-04

2.  Difference of refraction values between standard autorefractometry and Plusoptix.

Authors:  Camelia Margareta Bogdănici; Codrina Maria Săndulache; Rodica Vasiliu; Otilia Obadă
Journal:  Rom J Ophthalmol       Date:  2016 Oct-Dec

Review 3.  Advantages, limitations, and diagnostic accuracy of photoscreeners in early detection of amblyopia: a review.

Authors:  Irene Sanchez; Sara Ortiz-Toquero; Raul Martin; Victoria de Juan
Journal:  Clin Ophthalmol       Date:  2016-07-22

4.  Comparison of Autorefraction and Photorefraction with and without Cycloplegia Using 1% Tropicamide in Preschool Children.

Authors:  Ertuğrul Tan Yassa; Cihan Ünlü
Journal:  J Ophthalmol       Date:  2019-05-02       Impact factor: 1.909

5.  Comparison of Adult Refractive Disorder Measurements Using HandyRef-K, Retinomax, Plusoptix, and Table-top Autorefractometer Devices.

Authors:  Zeynep Seymen; Sinan Bekmez; Erdem Eris; Burcin Kepez Yildiz; Asli Vural; Tulin Ogreden; Irfan Perente
Journal:  Beyoglu Eye J       Date:  2021-06-08

6.  HandyRef-K: Comparison of the Latest Handheld Auto Refracto-keratometer with Retinomax and Plusoptix in Patients Younger than Three Years of Age.

Authors:  Zeynep Seymen; Esra Vural; Erdem Eris; Asli Vural; Tulin Ogreden; Onder Aslan; Ali Riza Cenk Celebi; Irfan Perente
Journal:  Beyoglu Eye J       Date:  2019-02-26

7.  Pediatric vision screening using the plusoptiX A12C photoscreener in Chinese preschool children aged 3 to 4 years.

Authors:  Dan Huang; Xuejuan Chen; Xiaohan Zhang; Yue Wang; Hui Zhu; Hui Ding; Jing Bai; Ji Chen; Zhujun Fu; Zijin Wang; Hu Liu
Journal:  Sci Rep       Date:  2017-05-17       Impact factor: 4.379

8.  Comparison of Plusoptix S12R photoscreener with cycloplegic retinoscopy and autorefraction in pediatric age group.

Authors:  Varun Saini; Usha K Raina; Anika Gupta; Jawahar Lal Goyal; Raffat Anjum; Pallavi Saini; Shantanu Kumar Gupta; Prateeksha Sharma
Journal:  Indian J Ophthalmol       Date:  2019-10       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.